FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2205004372> ?p ?o ?g. }

• W2205004372 endingPage "1351" @default.
• W2205004372 startingPage "1347" @default.
• W2205004372 abstract "OBJECTIVE: To examine the effect of didanosine (2′,3′-dideoxyinosine, ddI) on surrogate markers of HIV infection (CD4+ lymphocyte count, p24 antigen) and to evaluate the incidence of adverse effects from ddI. DESIGN: This study was performed as a retrospective chart review of patients who were enrolled in Bristol-Myers Squibb's expanded-access program for ddI. SETTING: Patient records were obtained from primary care physicians' offices. PATIENTS: Twenty-five HIV-infected patients diagnosed with AIDS or AIDS-related complex (ARC) who were intolerant of zidovudine (ZDV) therapy or deteriorating clinically despite ZDV therapy and were eligible for inclusion in the ddI expanded-access program. INTERVENTION: ddI was administered orally in a citrate-phosphate buffer every 12 hours. Patients were followed by their private physician on a monthly basis. MAIN OUTCOME MEASURES: Laboratory analysis at each month included CD4+ lymphocyte count, hemoglobin, hematocrit, serum amylase, uric acid, serum triglycerides, and p24 antigen. Mean CD4+ cell count, serum amylase, hemoglobin, and uric acid at each month during ddI therapy were compared with baseline concentrations for nine months. RESULTS: Patients had received prior ZDV therapy for an average of 15.5 months before starting ddI. Mean CD4+ cell counts increased from 53.9/mm 3 at baseline to 72.4/mm 3 after 4 months of therapy (p=0.04) but returned to concentrations comparable with those at baseline after 5 months. One case of documented pancreatitis, two cases of suspected pancreatitis, and nine cases of peripheral neuropathy occurred during ddI therapy. The estimated mean cumulative dose for the development of neuropathy was 1.16 g/kg, which is lower than previously reported. CONCLUSIONS: Patients who have received prolonged therapy with ZDV or who have low initial CD4+ counts may not have sustained increases in CD4+ counts from ddI therapy. Also, development of peripheral neuropathy may occur at lower cumulative doses in these patient populations." @default.
• W2205004372 created "2016-06-24" @default.
• W2205004372 creator A5053255995 @default.
• W2205004372 creator A5080630964 @default.
• W2205004372 date "1992-11-01" @default.
• W2205004372 modified "2023-09-25" @default.
• W2205004372 title "Didanosine Therapy in Patients Intolerant of or Failing Zidovudine Therapy" @default.
• W2205004372 cites W1968822999 @default.
• W2205004372 cites W1988065365 @default.
• W2205004372 cites W1991481307 @default.
• W2205004372 cites W2006959383 @default.
• W2205004372 cites W2059586894 @default.
• W2205004372 cites W2063750346 @default.
• W2205004372 cites W2085459671 @default.
• W2205004372 cites W2086462809 @default.
• W2205004372 cites W2131942108 @default.
• W2205004372 cites W2313243642 @default.
• W2205004372 cites W2317513349 @default.
• W2205004372 cites W2325115797 @default.
• W2205004372 cites W2333399282 @default.
• W2205004372 cites W2761049395 @default.
• W2205004372 doi "https://doi.org/10.1177/106002809202601101" @default.
• W2205004372 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1362093" @default.
• W2205004372 hasPublicationYear "1992" @default.
• W2205004372 type Work @default.
• W2205004372 sameAs 2205004372 @default.
• W2205004372 citedByCount "9" @default.
• W2205004372 countsByYear W22050043722013 @default.
• W2205004372 countsByYear W22050043722014 @default.
• W2205004372 crossrefType "journal-article" @default.
• W2205004372 hasAuthorship W2205004372A5053255995 @default.
• W2205004372 hasAuthorship W2205004372A5080630964 @default.
• W2205004372 hasConcept C126322002 @default.
• W2205004372 hasConcept C141071460 @default.
• W2205004372 hasConcept C197934379 @default.
• W2205004372 hasConcept C203014093 @default.
• W2205004372 hasConcept C2775967933 @default.
• W2205004372 hasConcept C2777447569 @default.
• W2205004372 hasConcept C2780216070 @default.
• W2205004372 hasConcept C2780727368 @default.
• W2205004372 hasConcept C2780959883 @default.
• W2205004372 hasConcept C3013748606 @default.
• W2205004372 hasConcept C71924100 @default.
• W2205004372 hasConcept C90924648 @default.
• W2205004372 hasConceptScore W2205004372C126322002 @default.
• W2205004372 hasConceptScore W2205004372C141071460 @default.
• W2205004372 hasConceptScore W2205004372C197934379 @default.
• W2205004372 hasConceptScore W2205004372C203014093 @default.
• W2205004372 hasConceptScore W2205004372C2775967933 @default.
• W2205004372 hasConceptScore W2205004372C2777447569 @default.
• W2205004372 hasConceptScore W2205004372C2780216070 @default.
• W2205004372 hasConceptScore W2205004372C2780727368 @default.
• W2205004372 hasConceptScore W2205004372C2780959883 @default.
• W2205004372 hasConceptScore W2205004372C3013748606 @default.
• W2205004372 hasConceptScore W2205004372C71924100 @default.
• W2205004372 hasConceptScore W2205004372C90924648 @default.
• W2205004372 hasIssue "11" @default.
• W2205004372 hasLocation W22050043721 @default.
• W2205004372 hasLocation W22050043722 @default.
• W2205004372 hasOpenAccess W2205004372 @default.
• W2205004372 hasPrimaryLocation W22050043721 @default.
• W2205004372 hasRelatedWork W2008878688 @default.
• W2205004372 hasRelatedWork W204038522 @default.
• W2205004372 hasRelatedWork W2044083862 @default.
• W2205004372 hasRelatedWork W2075050095 @default.
• W2205004372 hasRelatedWork W2102705913 @default.
• W2205004372 hasRelatedWork W2155455149 @default.
• W2205004372 hasRelatedWork W2322276116 @default.
• W2205004372 hasRelatedWork W2334005831 @default.
• W2205004372 hasRelatedWork W2415326996 @default.
• W2205004372 hasRelatedWork W2495009303 @default.
• W2205004372 hasVolume "26" @default.
• W2205004372 isParatext "false" @default.
• W2205004372 isRetracted "false" @default.
• W2205004372 magId "2205004372" @default.
• W2205004372 workType "article" @default.